Jpmorgan Chase & CO Alector, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Alector, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,728,823 shares of ALEC stock, worth $14 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,728,823
Previous 1,656,525
64.73%
Holding current value
$14 Million
Previous $7.52 Million
69.45%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ALEC
# of Institutions
167Shares Held
58.4MCall Options Held
57KPut Options Held
14.9K-
Black Rock Inc. New York, NY9.1MShares$46.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.46MShares$28 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.63MShares$23.8 Million0.8% of portfolio
-
Morgan Stanley New York, NY4.36MShares$22.3 Million0.0% of portfolio
-
State Street Corp Boston, MA2.62MShares$13.4 Million0.0% of portfolio
About Alector, Inc.
- Ticker ALEC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,563,904
- Market Cap $424M
- Description
- Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...